Camaschella C, Piperno A
Dipartimento di Scienze Biomediche e Oncologia Umana, Azienda Ospedaliera S. Luigi, Orbassano, CNR CIOS Turin, Italy.
Haematologica. 1997 Jan-Feb;82(1):77-84.
Hereditary hemochromatosis (HC) is an inborn error of iron metabolism leading to increased intestinal iron absorption and progressive iron overload. There have been definite advances in our knowledge of the pathogenesis and management of idiopathic hemochromatosis in recent years, which prompted us to review this subject.
The material examined in the present review includes articles and abstracts published in the journals covered by the Science Citation Index and Medline. In addition, both authors have been working in this field for several years and have contributed twelve of the papers cited in the references.
The disease is a late onset autosomic recessive condition, especially frequent in Caucasians. If unrecognized, severe clinical symptoms develop in mid-life related to organ failure. Early diagnosis prevents complications, since an intensive phlebotomy course removes excess iron and offers patients a normal life expectancy. Transferrin saturation is the first examination step, but liver biopsy is still essential for diagnosis and prognosis of HC. The biochemical defect is unknown. Positional cloning of the HC gene has led to the isolation of all the candidate region on the short arm of chromosome 6, telomeric to HLA-A. Recently a putative HC gene has been cloned from this region and found to be mutated in a large proportion of patients. The gene, known as HLA-H, is an atypical MHC class I gene. Although its biological function remains unknown, HLA-H is the first strong HC candidate gene. Molecular screening of patients and carriers is now possible in a significant portion of cases, thereby permitting better control of the disease. If it is unequivocally confirmed that the HLA-H gene is responsible for the disease, understanding of its biological function will provide information on the type and activity of the involved protein, revealing new insights into iron uptake and metabolism in humans.
遗传性血色素沉着症(HC)是一种铁代谢的先天性缺陷,导致肠道铁吸收增加和进行性铁过载。近年来,我们对特发性血色素沉着症的发病机制和治疗的认识有了明确进展,这促使我们对该主题进行综述。
本综述中查阅的资料包括发表在《科学引文索引》和《医学索引》所涵盖期刊上的文章和摘要。此外,两位作者均已在该领域工作数年,并贡献了参考文献中引用的12篇论文。
该疾病是一种迟发性常染色体隐性疾病,在白种人中尤为常见。如果未被识别,严重的临床症状会在中年时因器官衰竭而出现。早期诊断可预防并发症,因为强化放血疗程可去除多余的铁,并使患者预期寿命正常。转铁蛋白饱和度是首要检查步骤,但肝活检对于HC的诊断和预后仍至关重要。生化缺陷尚不清楚。HC基因的定位克隆已导致在6号染色体短臂上HLA - A端粒方向分离出所有候选区域。最近,一个假定的HC基因已从该区域克隆出来,并发现大部分患者存在该基因突变。该基因称为HLA - H,是一种非典型的MHC I类基因。尽管其生物学功能尚不清楚,但HLA - H是首个强有力的HC候选基因。现在,在相当一部分病例中可以对患者及其携带者进行分子筛查,从而更好地控制该疾病。如果明确证实HLA - H基因导致该疾病,对其生物学功能的了解将提供有关所涉及蛋白质的类型和活性的信息,揭示人类铁摄取和代谢的新见解。